ClinicalTrials.gg
Not yet recruitingNCT07850947Updated Sep 30, 2026

An Observational Study of Percutaneous Glomerular Filtration Rate (TGFR) in the Early Warning of Contrast-induced Acute Kidney Injury During the Peri-examination Period of Emergency Enhanced CT

An observational study in Contrast-associated Acute Kidney Injury, sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.

Primary conditionAcute Kidney InjuryRegistry: EmergenciesReclassifiedWhy we changed it
Registry
Emergencies — the first condition term the registry derived for this study.
ClinicalTrials.gg
Acute Kidney Injury
Why
  1. Emergencies describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Acute Kidney Injury.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Second Affiliated Hospital, Zhejiang University, School of Medicine · Observational

Updated Sep 30, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 168 studies in Acute Kidney Injury with a site in China — 46 open to participants now, 54 under way, 1 of them phase 3. Acute Kidney Injury · China.

Planned enrollment
101st of 105
30 · median 472
Started
2026
with 24 others
Observational
105 of 168
26 open now
Primary completion
2026-12
later than 21 of 53 live
Registered
167th of 168
by date

Among the 168 studies in Acute Kidney Injury with a site in China, this one is the 101st largest by planned enrollment of the 105 observational ones that give a count, is one of 25 that started in 2026, is one of 105 observational ones, reaches primary completion later than 21 of the 53 other live ones, and was the 167th registered.

Acute Kidney Injury

1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.

Browse Acute Kidney Injury studies →

Open to participants now

46 of the 168 studies in Acute Kidney Injury with a site in China are open now. Recruiting first, the newest first:

41 more — sign in →

All 46 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 230 Acute Kidney Injury studies recruiting now, 162 (70%) set no upper age limit and 35 (15%) stop at 75 or younger; 22 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 168 studies in Acute Kidney Injury with a site in China, or all of them as a file.
02

Study summary

This is a single-center, prospective observational study. We aim to evaluate the performance of transdermal glomerular filtration rate (TGFR) compared with baseline estimated glomerular filtration rate (eGFR) for early prediction of contrast-associated acute kidney injury (CA-AKI) in emergency patients scheduled for contrast-enhanced CT. Eligible participants are adult emergency patients with baseline eGFR between 15 and 120 mL/min/1.73m². TGFR monitoring will be performed during the peri-contrast CT period. We will collect clinical and laboratory data and follow up renal function after contrast exposure to analyze the predictive value of TGFR for CA-AKI. No extra therapeutic interventions will be applied in this study.

Read the detailed description

This is a single-center, prospective observational study conducted in the emergency department. Adult patients who require contrast-enhanced computed tomography (CT) examination and have baseline estimated glomerular filtration rate (eGFR) ranging from 15 to 120 mL/min/1.73m² will be consecutively enrolled. Transdermal glomerular filtration rate (TGFR) monitoring will be implemented throughout the peri-contrast CT period. Baseline demographic information, clinical characteristics, laboratory parameters and contrast agent-related data will be collected. Serum creatinine will be tested after contrast exposure to identify cases of contrast-associated acute kidney injury (CA-AKI). The primary objective is to assess the predictive performance of TGFR for CA-AKI compared with conventional baseline eGFR. No study-related therapeutic interventions will be performed. All clinical managements follow routine emergency clinical practice. The total planned sample size is 30 subjects.

03

Conditions studied

  • Contrast-associated Acute Kidney Injury

Browse trials for

Keywords

  • Contrast-associated acute kidney injury
  • Transdermal glomerular filtration rate
  • Emergency department
  • Contrast-enhanced CT
  • Acute kidney injury
04

In context

Acute Kidney Injury Reclassified

1,691 studies on the registry are indexed under Acute Kidney Injury; 393 are open to participants now.

This study's planned enrollment of 30 is below the median of 160 across 814 observational studies indexed under Acute Kidney Injury.

Browse Acute Kidney Injury studies →

Lead sponsor

Second Affiliated Hospital, Zhejiang University, School of Medicine is the lead sponsor of 100 studies on the registry; 68 are open to participants now.

Compared within Acute Kidney Injury, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Emergencies. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients aged ≥18 years receiving emergency iodinated contrast-enhanced CT scan. We will observe the incidence of contrast-associated acute kidney injury and continuous transdermal renal monitoring.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥18 years old.
  2. Undergoing emergency contrast-enhanced CT examination.
  3. Patients who agree to participate in this observational study.

Exclusion criteria

Exclusion Criteria:

  1. History of end-stage renal disease receiving renal replacement therapy.
  2. Known allergy to iodinated contrast media.
  3. Pregnancy.
  4. Unable to complete 72-hour follow-up after contrast administration.
06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Emergency contrast-enhanced CT patients

    Adult emergency patients scheduled for contrast-enhanced CT. TGFR monitoring will be performed during peri-contrast period. No therapeutic intervention will be applied; all clinical management follows routine practice.

    Device: Transdermal glomerular filtration rate (TGFR) monitoring

Interventions

  • DeviceTransdermal glomerular filtration rate (TGFR) monitoring

    Non-invasive transdermal glomerular filtration rate measurement performed during peri-contrast period for research observation only. No therapeutic treatment will be delivered. All clinical care remains routine standard care.

07

What researchers measure

Primary outcomes

  1. Incidence of contrast-associated acute kidney injury (CA-AKI)

    Incidence of contrast-associated acute kidney injury within 72 hours after contrast media administration, defined by serum creatinine elevation criteria.

    Time frame: Within 72 hours after contrast injection

08

Study locations

1 site
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data (IPD) of this study will not be shared with external researchers, to protect patient privacy and comply with Chinese healthcare data protection regulations.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Dec 2026, 3 months later.

Of 350 non-industry observational studies under Acute Kidney Injury, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 3 months is below that.

Counting every sponsor, half of 365 studies reached it within 24 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2026
First posted
Sep 30, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2027
Last update
Sep 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 30, 2026
Show all 1 update
  1. Sep 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07850947
Responsible party
Sponsor
First posted
Sep 30, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 30, 2026

Study contacts

Shanxiang Xu, MD
Contact
2201027@zju.edu.cn
+8613757119126

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion